依拉环素（TP-434）在体外对由尿路致病性大肠杆菌形成的生物膜具有活性。
Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli.
作者信息
Grossman Trudy H, O'Brien William, Kerstein Kathryn O, Sutcliffe Joyce A
机构信息
Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA
Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA.
出版信息
Antimicrob Agents Chemother. 2015 Apr;59(4):2446-9. doi: 10.1128/AAC.04967-14. Epub 2015 Jan 26.
Abstract
Eravacycline (formerly TP-434) was evaluated in vitro against pre-established biofilms formed by a uropathogenic Escherichia coli strain. Biofilms were eradicated by 0.5 μg/ml eravacycline, which was within 2-fold of the MIC for planktonic cells. In contrast, colistin and meropenem disrupted biofilms at 32 and 2 μg/ml, respectively, concentrations well above their respective MICs of 0.5 and 0.03 μg/ml. Gentamicin and levofloxacin eradicated biofilms at concentrations within 2-fold of their MICs.
摘要
对依拉环素（原TP - 434）进行了体外评估，以检测其对由一种尿路致病性大肠杆菌菌株形成的预先建立的生物膜的作用。0.5μg/ml的依拉环素可根除生物膜，该浓度在浮游细胞最低抑菌浓度（MIC）的2倍范围内。相比之下，黏菌素和美罗培南分别在32μg/ml和2μg/ml时破坏生物膜，这些浓度远高于它们各自0.5μg/ml和0.03μg/ml的MIC。庆大霉素和左氧氟沙星在其MIC的2倍范围内的浓度时可根除生物膜。
相似文献
1
Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli.依拉环素（TP-434）在体外对由尿路致病性大肠杆菌形成的生物膜具有活性。
Antimicrob Agents Chemother. 2015 Apr;59(4):2446-9. doi: 10.1128/AAC.04967-14. Epub 2015 Jan 26.
2
Disruption of Membrane by Colistin Kills Uropathogenic Escherichia coli Persisters and Enhances Killing of Other Antibiotics.黏菌素破坏细胞膜可杀死尿路致病性大肠杆菌持留菌并增强其他抗生素的杀菌效果。
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6867-6871. doi: 10.1128/AAC.01481-16. Print 2016 Nov.
3
Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.磷霉素、替加环素、黏菌素和庆大霉素对异物感染模型中产超广谱β-内酰胺酶大肠埃希菌的活性。
Antimicrob Agents Chemother. 2013 Mar;57(3):1421-7. doi: 10.1128/AAC.01718-12. Epub 2013 Jan 7.
4
Inhibition and Inactivation of Uropathogenic Biofilms on Urinary Catheters by Sodium Selenite.亚硒酸钠对尿路致病性生物膜在导尿管上的抑制和失活作用。
Int J Mol Sci. 2018 Jun 7;19(6):1703. doi: 10.3390/ijms19061703.
5
Inhibition of the adhesion to catheters of uropathogenic Escherichia coli by sub-inhibitory concentrations of cefotaxime.亚抑菌浓度头孢噻肟抑制泌尿道致病性大肠埃希菌黏附导管。
Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):150-6. doi: 10.1016/j.ejogrb.2010.12.034. Epub 2011 Jan 28.
6
Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype.依拉环素对2011年从美国退伍军人中分离出的大肠埃希菌临床菌株的活性与共耐药表型及序列型131基因型的关系
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1888-91. doi: 10.1128/AAC.02403-15.
7
Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection.磷霉素氨丁三醇对尿路感染患者分离的产脲原性大肠埃希菌生物膜和细胞内细菌群落的作用。
Pathog Dis. 2019 Apr 1;77(3). doi: 10.1093/femspd/ftz022.
8
Effect of different antibiotics on biofilm produced by uropathogenic Escherichia coli isolated from children with urinary tract infection.不同抗生素对从尿路感染患儿分离出的尿路致病性大肠杆菌产生的生物膜的影响。
Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx053.
9
Cell death and biomass reduction in biofilms of multidrug resistant extended spectrum β-lactamase-producing uropathogenic Escherichia coli isolates by 1,8-cineole.1,8-桉叶素对产超广谱β-内酰胺酶多重耐药尿路致病性大肠埃希菌生物膜中细胞死亡和生物量减少的影响。
PLoS One. 2020 Nov 5;15(11):e0241978. doi: 10.1371/journal.pone.0241978. eCollection 2020.
10
Autochthonous case of mobile colistin resistance gene mcr-1 from a uropathogenic Escherichia coli isolate in Sétif Hospital, Algeria.来自阿尔及利亚塞蒂夫医院一株尿路致病性大肠杆菌分离株的可移动黏菌素耐药基因mcr-1的本地病例。
J Glob Antimicrob Resist. 2019 Dec;19:356-357. doi: 10.1016/j.jgar.2019.10.006. Epub 2019 Nov 9.
引用本文的文献
1
Antibiofilm approaches as a new paradigm for treating infections.抗生物膜方法作为一种治疗感染的新范例。
Prog Biomed Eng (Bristol). 2024 Apr;6(2). doi: 10.1088/2516-1091/ad1cd6. Epub 2024 Feb 9.
2
Intrinsic antimicrobial resistance: Molecular biomaterials to combat microbial biofilms and bacterial persisters.固有抗菌耐药性：用于对抗微生物生物膜和细菌持久体的分子生物材料。
Biomaterials. 2024 Dec;311:122690. doi: 10.1016/j.biomaterials.2024.122690. Epub 2024 Jun 28.
3
Carbapenem-Resistant in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives.碳青霉烯类耐药菌引起的尿路感染：从生物学研究进展到新兴治疗选择。
Medicina (Kaunas). 2024 Jan 26;60(2):214. doi: 10.3390/medicina60020214.
4
In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria-A Pilot Study in Bulgaria.五种新批准抗生素对产碳青霉烯酶肠杆菌的体外抗菌活性——保加利亚的一项初步研究
Antibiotics (Basel). 2024 Jan 15;13(1):81. doi: 10.3390/antibiotics13010081.
5
In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland.依拉环素对波兰中部产碳青霉烯酶革兰阴性杆菌临床分离株的体外活性
Biomedicines. 2023 Jun 21;11(7):1784. doi: 10.3390/biomedicines11071784.
6
Pharmacodynamics of Moxifloxacin, Meropenem, Caspofungin, and Their Combinations against Polymicrobial Interkingdom Biofilms.莫西沙星、美罗培南、卡泊芬净及其组合对多微生物属生物膜的药效动力学。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0214921. doi: 10.1128/AAC.02149-21. Epub 2021 Dec 20.
7
Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.碳青霉烯类耐药肠杆菌科感染的治疗：最新进展和未来方向。
Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2053-2068. doi: 10.1007/s10096-021-04296-1. Epub 2021 Jun 24.
8
[New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].用于多重耐药病原体所致严重感染的新型抗生素：确定性治疗与升级治疗
Anaesthesist. 2019 Nov;68(11):785-800. doi: 10.1007/s00101-019-00646-z.
9
Eravacycline, a newly approved fluorocycline.依拉环素，一种新批准的氟环素。
Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1787-1794. doi: 10.1007/s10096-019-03590-3. Epub 2019 Jun 7.
10
A steam-based method to investigate biofilm.基于蒸汽的生物膜研究方法。
Sci Rep. 2018 Aug 29;8(1):13040. doi: 10.1038/s41598-018-31437-y.
本文引用的文献
1
Escherichia coli biofilms have an organized and complex extracellular matrix structure.大肠杆菌生物膜具有有组织和复杂的细胞外基质结构。
mBio. 2013 Sep 10;4(5):e00645-13. doi: 10.1128/mBio.00645-13.
2
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.依拉环素（TP-434）的抗菌活性，一种新型氟环素，针对医院和社区病原体。
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
3
Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of ceftazidime.在头孢他啶存在的情况下，成熟的铜绿假单胞菌生物膜比年轻的生物膜更为普遍。
Antimicrob Agents Chemother. 2012 Sep;56(9):4976-9. doi: 10.1128/AAC.00650-12. Epub 2012 Jul 9.
4
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.以新型氟环素抗生素 TP-434 为对象和为靶点的作用机制研究。
Antimicrob Agents Chemother. 2012 May;56(5):2559-64. doi: 10.1128/AAC.06187-11. Epub 2012 Feb 21.
5
Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.氟环素。1. 7-氟-9-吡咯烷酮基乙酰胺基-6-脱甲基-6-去氧四环素：一种具有强大、广谱抗菌活性的药物。
J Med Chem. 2012 Jan 26;55(2):597-605. doi: 10.1021/jm201465w. Epub 2012 Jan 4.
6
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.面对多种抗生素，尿路致病性大肠杆菌仍持续存在。
Antimicrob Agents Chemother. 2010 May;54(5):1855-63. doi: 10.1128/AAC.00014-10. Epub 2010 Mar 15.
7
Evolving concepts in biofilm infections.生物膜感染中的不断演变的概念。
Cell Microbiol. 2009 Jul;11(7):1034-43. doi: 10.1111/j.1462-5822.2009.01323.x. Epub 2009 Apr 6.
8
Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms.铜绿假单胞菌生物膜中耐黏菌素和十二烷基硫酸钠细胞的分化与分布
J Bacteriol. 2007 Jan;189(1):28-37. doi: 10.1128/JB.00720-06. Epub 2006 Oct 13.
9
Survival strategies of infectious biofilms.传染性生物膜的生存策略。
Trends Microbiol. 2005 Jan;13(1):34-40. doi: 10.1016/j.tim.2004.11.010.
10
Persister cells and tolerance to antimicrobials.持留菌与抗菌耐受性。
FEMS Microbiol Lett. 2004 Jan 15;230(1):13-8. doi: 10.1016/S0378-1097(03)00856-5.
Zotero 插件